微波消融/阿帕替尼治疗中晚期肝细胞癌的研究进展  

Advances in microwave ablation/apatinib in the treatment of advanced hepatocellular carcinoma

作　　者：杨耕夫 余松远[1] YANG Geng-fu;YU Song-yuan(Department of Wuhan University of science and technology,Tianyou Hospital,Wuhan 430000,China)

机构地区：[1]湖北省武汉科技大学附属天佑医院超声介入科

出　　处：《消化肿瘤杂志（电子版）》2019年第3期190-194,共5页Journal of Digestive Oncology(Electronic Version)

基　　金：湖北省卫生健康委员会基金项目(WJ2019H231)

摘　　要：肝癌是最常见恶性肿瘤之一。针对中晚期肝癌的治疗是世界性的难题,目前有介入肿瘤治疗、分子靶向药物治疗等多种综合性治疗措施。微波消融作为介入治疗的一种,具有安全、有效、经济、实用等优点而在临床上广泛开展,并在与肝动脉化疗栓塞的联合治疗中显现出疗效;阿帕替尼作为国产新型分子靶向药物,相对于同类药物,具有经济、副反应少等优势,并在晚期肝癌的治疗上取得了令人期待的结果;而微波消融与阿帕替尼作为有前途的治疗方案,其远期疗效仍存在争议,需进一步研究。本文旨在就微波消融与阿帕替尼治疗中晚期肝癌的原理、临床疗效与安全性的研究进展予以综述。Hepatocellular carcinoma(HCC)is one of the common malignant tumor in the world.The treatment of advanced hepatocellular carcinoma(HCC)is a worldwide problem.As a kind of interventional therapy,microwave ablation is widely used in clinical practice because of its safety,effectiveness,economy and practicality.As a new molecular targeted drug in China,apatinib has the advantages of economy and fewer side effects compared with similar drugs,and has achieved desirable results in the treatment of advanced liver cancer.As the promising treatment options,microwave ablation(MWA)and apatinib remains some controversial issues in the combinations and long-term efficacy.The progress of the theory,clinical efficacy and safety of MWA and apatinib were reviewed in this article.

关 键 词：微波消融 阿帕替尼 中晚期肝癌 分子靶向治疗 联合疗法 

分 类 号：R73[医药卫生—肿瘤]